An analysis of data from 41 health care systems participating in the National Patient-Centered Clinical Research Network found lower use of monoclonal antibody therapies for patients who are Black, Asian or other races compared with white and non-Hispanic patients between November 2020 and August 2021, the Centers for Disease Control and Prevention reported Friday. Among all patients with positive SARS-CoV-2 test results, the overall use of mAb was infrequent, with mean monthly use at 4% or less for all racial and ethnic groups.

In other news, the CDC Friday released updated COVID-19 masking information for consumers to reflect the latest science. The update lays out the protection provided by available masks and respirators, noting that some provide better protection than others.

Headline
Joy A. Rhoden, AHA senior vice president and executive director of health outcomes and care transformation, explores the economic impact of health disparities…
Blog
Public
Hospital and health system leaders are navigating workforce shortages, reimbursement pressures, caring for a sicker patient population and rising operational…
Headline
The AHA Aug. 11 released a new resource guide designed to address a critical gap by helping leaders understand and quantify the economic burden of…
Headline
The AHA is now offering custom innovation summits — proven, high-impact workshops designed to convene health care leaders and co-…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Blog
Despite medical advancements, maternal mortality rates have doubled since 1987. Yet more than 80% of pregnancy-related deaths have been deemed preventable.We…